Clinical Trials on Primary Breast Cancer in China

Total 10414 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Targeted Therapy | HR+/HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

HR Positive HER2 Negative Advanced Breast Cancer

China
Fudan University

Recruiting

ARX788 in Breast Cancer With Low Expression of HER2

Breast Cancer With Low Expression of HER2

China
Beta Pharma (Suzhou) Co., Ltd.

Recruiting

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Advanced Solid Tumor | HR+/HER2- Breast Cancer

China
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Fudan University

Completed

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

Metastatic Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Breast Cancer Recurrent

China
Cancer Institute and Hospital, Chinese Academy...
Novartis Pharmaceuticals

Unknown

Everolimus trIal for Advanced prememopausaL Breast Cancer Patients (MIRACLE)

Metastatic Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

HER2+ Breast Cancer

China
Sun Yat-sen University
Chengdu Biostar Pharmaceuticals

Not yet recruiting

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Neoadjuvant Therapies for HER2+ Breast Cancer

China
Shi Yanxia

Recruiting

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer (PERS)

Breast Cancer | Effects of Chemotherapy | Breast Cancer Model

China
Xijing Hospital

Unknown

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

HR-positive,HER2-negative in Advanced Breast Cancer

China
Hongmei Zheng

Recruiting

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

Endocrine Therapy | Breast Cancer Female

China
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (HER2-VIP)

HER2-positive Advanced Breast Cancer

China
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Advanced Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University; First People's Hospital of Foshan

Completed

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Metastatic Breast Cancer

China
Abbisko Therapeutics Co, Ltd

Enrolling by invitation

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Triple Negative Breast Cancer

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
Fudan University

Active, not recruiting

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Triple Negative Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

HER2-positive Breast Cancer | Adjuvant Therapy

China
Second Affiliated Hospital, School of Medicine,...
Women's Hospital School Of Medicine Zhejiang University; Zhejiang Provincial... and other collaborators

Recruiting

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

HER2-negative Breast Cancer | Neoadjuvant Chemotherapy

China
First Affiliated Hospital Xi'an Jiaotong University

Unknown

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer (PET)

Estrogen Receptor-positive Breast Cancer | Fulvestrant

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Huanxing Cancer Hospital; Cancer Hospital, Chinese Academy of Medical...

Recruiting

Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer (AMENDER)

Early-stage Breast Cancer

China
Fudan University

Recruiting

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

China
Hebei Medical University Fourth Hospital
Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Triple Negative Breast Cancer | Nab-paclitaxel

China
Peking University People's Hospital

Recruiting

Study on Classification Method of Indocyanine Green Lymphography Based on Deep Learning (BCRL；ICG)

Breast Cancer Related Lymphedema | Deep Learning

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Metastatic Breast Cancer

China
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

Breast Cancer Recurrent

China
Shanghai Juncell Therapeutics
Shanghai 10th People's Hospital

Recruiting

Study on TIL for the Treatment of Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of Immunotherapy

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer

ER Positive/HER2 Low Breast Cancer

China
DualityBio Inc.
BioNTech SE

Recruiting

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

HER2-positive Breast Cancer

China
Guangdong Provincial People's Hospital

Completed

Neoadjuvant Endocrine Therapy in Breast Cancer

Highly Endocrine Responsive Operable Breast Cancer

China
Organisation for Oncology and Translational Research

Unknown

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

ER Positive, HER2 Negative Breast Cancer

China
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
Xijing Hospital

Recruiting

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer (ACNTBC)

Breast Cancer Stage II

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

Breast Cancer | Breast Cancer Female

China
Xin-Wu Cui
Hubei Cancer Hospital; First Affiliated Hospital of Kunming Medical University and other collaborators

Recruiting

Identification of Benign and Malignant Breast Nodules Using Ultrasound-modulated Optical Tomography: A Multicenter Study

Breast Cancer Female

China
Min Yan, MD
Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Breast Cancer Recurrent

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Aromatherapy in the Treatment of Early Breast Cancer

Early Breast Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
West China Hospital

Completed

A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients

Breast Cancer Female

China
Peking University People's Hospital

Recruiting

Assessment of Breast Cancer-Related Arm Lymphedema

Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Advanced or Metastatic Breast Cancer

China

Clinical Trials on Primary Breast Cancer in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations